Yijun Liu, Eugenia Zah, Carlos Arbelaez, Haejin Kim, Edwige Gros, Ranelle Buck, Kayley Cox, Sungeun Kim, Martina Kopp, Kathryn Henckels, Jennitte Stevens
Autologous cell therapy has proven to be an effective treatment for hematological malignancies. Cell therapies for solid tumors are on the horizon, however the high cost and complexity of manufacturing these therapies remain a challenge. Routinely used open steps to transfer cells and reagents through unit operations further burden the workflow reducing efficiency and increasing the chance for human error. Here we describe a fully closed, autologous bioprocess generating engineered TCR-T cells. This bioprocess yielded 5-12 × 10e9 TCR-expressing T cells, transduced at low multiplicity of infections, within 7-10 days, and cells exhibited an enriched memory T-cell phenotype and enhanced metabolic fitness...
April 7, 2023: Biotechnology and Bioengineering